Holen Sie sich die Stockscreener-App
0.05
0.00%
0.00
Handel nachbörslich:
.05
Telesis Bio Inc Aktie (TBIO) Neueste Nachrichten
Regeneron to deploy Telesis Bio’s Gibson SOLA at R&D facilities - Yahoo
Telesis Bio and Regeneron Partner on Gene Synthesis - Technology Networks
Regeneron (REGN) Adopts Telesis Bio's Gene Synthesis Platform | - GuruFocus
Regeneron Pharmaceuticals, Inc. (REGN) Licenses Gibson SOLA Platform to Boost R&D Efficiency - Yahoo
Regeneron Pharmaceuticals (NasdaqGS:REGN) Adopts Innovative Technology for Faster Drug Discovery - Yahoo Finance
Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis - BioSpace
Telesis Bio (NASDAQ:TBIO) Stock Price Up 28.9% – Here’s Why - American Banking and Market News
Telesis Bio (NASDAQ:TBIO) Trading Up 28.9% – Still a Buy? - Defense World
TELESIS BIO INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus
Telesis Bio (NASDAQ:TBIO) Trading Down 23.1% – Here’s Why - Defense World
$21M Investment Powers Telesis Bio's Game-Changing Overnight DNA Synthesis Technology - StockTitan
Telesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA Synthesis - Business Wire
Telesis Bio (NASDAQ:TBIO) Trading 27.3% Higher – Should You Buy? - Defense World
Financial Contrast: Telesis Bio (NASDAQ:TBIO) and Prenetics Global (NASDAQ:PRE) - Defense World
Nuclera appoints William J. Kullback as Non-Executive Director - Cambridge Network
Telesis Bio (NASDAQ:TBIO) Trading 11.6% Higher – Here’s What Happened - Defense World
Telesis Bio (NASDAQ:TBIO) Shares Down 2.4% – Time to Sell? - Defense World
Telesis Bio (NASDAQ:TBIO) Stock Price Down 9.5% – Should You Sell? - Defense World
Carver Bancorp Leads 3 Noteworthy US Penny Stocks - simplywall.st
Telesis Bio (NASDAQ:TBIO) Shares Down 2.7% – What’s Next? - Defense World
Telesis Bio, Inc. announced that it has received $3 million in funding - Marketscreener.com
Telesis Bio (NASDAQ:TBIO) Shares Up 15.5% – Time to Buy? - Defense World
Telesis Bio secures $3 million in promissory notes - Investing.com
Telesis Bio Inc. Faces Financial Challenges Amidst Revenue Decline - TipRanks
Telesis Bio's Chief Legal Officer To Leave Post This Week - Law360
Telesis Bio Announces Departure of Chief Legal Officer - TipRanks
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.62% - MSN
Why Telesis Bio Shares Are Trading Higher By Around 110%; Here Are 20 Stocks Moving Premarket - MSN
Telesis Bio stock gains on Danaher deal (NASDAQ:TBIO) - Seeking Alpha
Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis - Yahoo Finance
Nasdaq Surges 400 Points; US Jobless Claims Fall To 219,000 - Benzinga
Dow Tumbles 350 Points; US Inflation Rate Slows In August - Benzinga
Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market - Yahoo Finance
Telesis Bio Names CEO Eric Esser as Chair After Five Board Members Resign - MarketWatch
Telesis Bio completes sale of subsidiary EtonBio - Investing.com
Enzymatic DNA Synthesis Market Size & Share Report, 2030 - Grand View Research
Telesis Bio Reports Second Quarter and First Half 2024 Financial Results - Yahoo Finance
Telesis Bio Reports First Quarter 2024 Financial Results - Yahoo Finance
Telesis Bio Announces Reverse Stock Split - Yahoo Finance
Telesis Bio appoints new CEO as founder steps down - Investing.com
Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results, Business Wires News - AsiaOne
Why Is Charge Enterprises (CRGE) Stock Down 41% Today? - InvestorPlace
Telesis Bio Announces Commercial Release of BioXp® NGS Library Prep Kit for WGS - The Korea Bizwire
Telesis Bio to Report Second Quarter Financial Results on Thursday, August 10, 2023, Business Wires News - AsiaOne
Telesis Bio Announces First Commercial Shipment of BioXp® Select DNA Cloning Kit - Technology Networks
Telesis Bio to Present at Jefferies Healthcare Conference 2023 - Koreabizwire
Sidley Represents Northpond Ventures in Its PIPE Investment in Telesis Bio Inc. - Sidley Austin LLP
Telesis Bio Announces Closing of $28.0 Million Private Placement of Preferred Stock and Warrants to Purchase an Additional $46.2 Million of Common Stock - Koreabizwire
Telesis Bio to Present at SynBioBeta 2023 - Koreabizwire
Blue Bird, First Solar rise; Harrow Health, Telesis Bio fall - Daily Sentinel Star
Telesis Bio, Inc. (NASDAQ:TBIO) Q4 2022 Earnings Call Transcript - Insider Monkey
Telesis Bio, Inc.'s (NASDAQ:TBIO) Shift From Loss To Profit - Yahoo Finance
Enzymatic DNA Synthesis Market Worth $2.24 Billion, by 2028 - GlobeNewswire
Codex DNA (NASDAQ:DNAY) CEO Todd Nelson Details the Investment Opportunity for mRNA and DNA Replication - The Wall Street Transcript
Interview with the President and CEO: Codex DNA, Inc. (NASDAQ:DNAY) - The Wall Street Transcript
Codex DNA Finishes 2021 Strong with Promising Pfizer Partnership - BioSpace
Codex DNA buys Eton Bioscience for $13m as San Diego synthetic biology firms join forces - The San Diego Union-Tribune
Telesis Bio (OTC:TBIO) Stock Quotes, Forecast and News Summary - Benzinga
TBIOTRANSLATE BIO, INC. Latest Stock News & Market Updates - Stock Titan
0.36%
1.38%
Kapitalisierung:
|
Volumen (24h):